GSH, L-Glutathione, Reduced Glutathione
Evidence Grade E — Very limited evidence. 0 published studies. 256 registered clinical trials.
Glutathione is the body's primary built-in antioxidant — a tripeptide found in virtually every human cell. While technically a peptide, it functions as a metabolic workhorse rather than a signalling molecule. Oral supplements, liposomal formulations, and intravenous infusions are widely marketed in wellness and skin-lightening contexts. It has no pharmaceutical approval for any therapeutic use.
No published studies found on PubMed.
Glutathione has no pharmaceutical marketing authorisation for any therapeutic indication. A 6-month randomised controlled trial of oral glutathione showed increased blood levels and immune cell function. Smaller studies have investigated skin-lightening effects.
The evidence base for supplemental glutathione is mixed. Oral bioavailability has historically been questioned, though liposomal formulations may improve absorption. Intravenous glutathione is marketed through wellness clinics but has not been evaluated in rigorous clinical trials for any specific indication. Glutathione is a naturally occurring molecule with well-characterised biochemistry — the question is whether supplementation provides clinically meaningful benefit.
Glutathione's biochemistry is well established: it neutralises reactive oxygen species, participates in detoxification reactions, and maintains other antioxidants in their active forms. These are normal cellular functions. The therapeutic question is whether exogenous supplementation meaningfully augments these processes beyond what the body already produces — and whether this translates to clinical benefit.
Research suggests a 6-month randomised trial established that oral glutathione supplements do raise blood levels, resolving an earlier debate about bioavailability. Small trials have shown skin-lightening effects. Safety for oral supplementation appears excellent. However, no large-scale placebo-controlled trials (over 500 participants) exist for any clinical outcome, no data extend beyond 6 months, and most trials are small (20-80 participants) with high individual variability. Intravenous glutathione infusions marketed through wellness clinics have not been evaluated in rigorous trials. Some regulatory agencies have issued advisories against IV glutathione for skin whitening.
Expanded Access Treatment Protocol With DCA for Patients With PDCD
Tolerability of Enteral NAC in Infants
Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
Evaluation of the Efficacy of Oral Tranexamic Acid and Glutathione-assisted Microneedling in Treatment of Melasma
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 3
Health Canada Market Authorisation
FDA SUPPL 4
FDA SUPPL 6
FDA SUPPL 7
FDA SUPPL 5
FDA SUPPL 8
FDA SUPPL 11
FDA SUPPL 10
FDA SUPPL 12
FDA SUPPL 13
FDA SUPPL 15
FDA SUPPL 18
FDA SUPPL 14
FDA SUPPL 16
FDA SUPPL 19
FDA SUPPL 21
FDA SUPPL 24
FDA SUPPL 26
FDA SUPPL 25
FDA SUPPL 17
FDA SUPPL 27
FDA SUPPL 23
FDA SUPPL 29
FDA SUPPL 28
FDA SUPPL 30
FDA SUPPL 31
FDA SUPPL 33
FDA SUPPL 34
FDA SUPPL 32
FDA SUPPL 35
FDA SUPPL 36
FDA SUPPL 37
FDA SUPPL 38
FDA SUPPL 39
FDA SUPPL 40
FDA SUPPL 41
FDA SUPPL 52
FDA SUPPL 53
FDA SUPPL 54
FDA SUPPL 55
FDA SUPPL 56
FDA SUPPL 60
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
